FDA OKs Crizotinib for Myofibroblastic Tumors FDA OKs Crizotinib for Myofibroblastic Tumors
The tyrosine kinase inhibitor has already been approved for certain patients with non-small cell lung cancer and anaplastic large cell lymphoma.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer